Benefits of statin therapy within a year after kidney transplantation

Seung Hyuk Yim,Hyun Jeong Kim,Han Ro,Jung-Hwa Ryu,Myung-Gyu Kim,Jae Berm Park,Chan-Duck Kim,Seungyeup Han,Sik Lee,Jaesok Yang,Kyu Ha Huh,Myoung Soo Kim,Juhan Lee

DOI: https://doi.org/10.1038/s41598-024-52513-6

IF: 4.6

2024-01-25

Scientific Reports

Abstract:Cardiovascular disease remains a leading cause of morbidity and mortality after kidney transplantation (KT). Although statins reduce cardiovascular risk and have renal benefits in the general population, their effects on KT recipients are not well-established. We studied the effects of early statin use (within 1-year post-transplantation) on long-term outcomes in 714 KT recipients from the Korean cohort study for outcome in patients with KT. Compared with the control group, statin group recipients were significantly older, had a higher body mass index, and had a higher prevalence of diabetes mellitus. During a median follow-up of 85 months, 74 graft losses occurred (54 death-censored graft losses and 20 deaths). Early statin use was independently associated with lower mortality (hazard ratio, 0.280; 95% confidence interval 0.111–0.703) and lower death-censored graft loss (hazard ratio, 0.350; 95% confidence interval 0.198–0.616). Statin therapy significantly reduced low-density lipoprotein cholesterol levels but did not decrease the risk of major adverse cardiovascular events. Biopsy-proven rejection and graft renal function were not significantly different between statin and control groups. Our findings suggest that early statin use is an effective strategy for reducing low-density lipoprotein cholesterol and improving patient and graft survival after KT.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the impact of early use of statins on the long - term survival rate of patients and the function of transplanted kidneys after renal transplantation. Specifically, the researchers hope to understand whether starting to use statins within the first year after renal transplantation can: 1. **Reduce the risk of death**: By analyzing the mortality data during the follow - up period, explore whether early use of statins can significantly reduce the all - cause mortality of patients. 2. **Reduce the loss of transplanted kidneys**: Study whether early use of statins can reduce the death - censored loss rate of transplanted kidneys (that is, exclude the loss of transplanted kidneys due to patient death). 3. **Improve blood lipid levels**: Evaluate the impact of statins on low - density lipoprotein cholesterol (LDL - C) levels and whether this impact helps to reduce the risk of cardiovascular diseases. 4. **Not affect the incidence of acute rejection**: Explore whether the use of statins will affect the incidence of acute rejection after transplantation, especially cell - mediated rejection (TCMR) and antibody - mediated rejection (AMR). ### Research background Cardiovascular diseases (CVD) are still the main causes of death and morbidity in renal transplantation (KT) recipients. Although renal transplantation can reduce the risk of cardiovascular diseases, compared with the general population, renal transplantation recipients still face a higher risk of cardiovascular diseases. In addition, the use of immunosuppressants may lead to metabolic changes and increase the risk of hyperlipidemia, and hyperlipidemia is a major risk factor for cardiovascular diseases. Therefore, it is of great significance to study the efficacy of statins in renal transplantation recipients. ### Main findings - **Survival rate**: Early use of statins significantly reduced the risk of death (adjusted hazard ratio [aHR] 0.280; 95% confidence interval 0.111 - 0.704; p = 0.007), and significantly reduced the death - censored loss rate of transplanted kidneys (aHR 0.231; 95% confidence interval 0.126 - 0.424; p < 0.001). - **Blood lipid levels**: Statins significantly reduced low - density lipoprotein cholesterol (LDL - C) levels, but did not significantly reduce the risk of major adverse cardiovascular events (MACE). - **Acute rejection**: The use of statins did not significantly affect the incidence of acute rejection, although the trough concentration of Tacrolimus in the statin group was lower. ### Conclusion The results of this study indicate that early use of statins in renal transplantation recipients can effectively reduce low - density lipoprotein cholesterol levels and is related to the improvement of the survival rates of patients and transplanted kidneys. However, statins did not significantly reduce the risk of major adverse cardiovascular events, nor did they significantly affect the incidence of acute rejection. These findings provide an important reference for further research on the application of statins in renal transplantation recipients.

Benefits of statin therapy within a year after kidney transplantation

Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis

The Effect and Underlying Mechanism of Statins in the Prevention of Post-Contrast Acute Kidney Injury: A Multicenter Retrospective Observational Study

Outcomes of Liver–kidney Transplantation in Patients with Primary Hyperoxaluria: an Analysis of the Scientific Registry of Transplant Recipients Database

Statin intensity and risk for cardiovascular events after heart transplantation

Preoperative Statin Therapy and Heart Transplantation Outcomes

Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes.

The Impact of Statin Intensity on the Early Progression of Cardiac Allograft Vasculopathy

Statin use and in-hospital outcomes among chronic kidney disease patients: a retrospective cohort study

Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan

Renal Outcomes After Simultaneous Liver‐Kidney Transplantation: Results from the US Multicenter Simultaneous Liver‐Kidney Transplantation Consortium

Statin-induced Rhabdomyolysis in Renal Transplant Recipients: Two Cases Reports

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Clinical implications of changes in metabolic syndrome status after kidney transplantation: a nationwide prospective cohort study

Management of blood lipids in post-kidney transplant patients: a systematic review and network meta-analysis

Effect of Statin Therapy on Cardiovascular Outcome in Stroke Patients with Low Baseline Low‐Density Lipoprotein Cholesterol

Clinical Analysis of 2520 Renal Transplantations in One Center

Optimizing Outcomes in Heart Transplantation: The Role of High‐Intensity Statin Therapy

Statin Use and the Progression of Coronary Artery Calcification in CKD: Findings From the KNOW-CKD Study

Inhibition of Proprotein Convertase Subtilisin/Kexin-9 After Kidney Transplant: Single-Center Experience Among Patients With High Cardiovascular Risk.